Gene therapy for dopamine replacement in Parkinson's disease

Science Translational Medicine

Volumn 1, Issue 2, 2009, Pages

  Björklund, Anders ^a   Björklund, Tomas ^a   Kirik, Deniz ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE;

ARTICLE; BIOSYNTHESIS; GENE THERAPY; GENE VECTOR; HUMAN; PARKINSON DISEASE;

DOPAMINE; GENE THERAPY; GENETIC VECTORS; HUMANS; PARKINSON DISEASE;

EID: 76949092638     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3000350     Document Type: Review

References (35)

1. A. Carlsson, M. Lindqvist, T. Magnusson, 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 180, 1200 (1957).
2. A. Carlsson, M. Lindqvist, T. Magnusson, B. Waldeck, On the presence of 3-hydroxytyramine in brain. Science 127, 471 (1958).
3. O. Hornykiewicz, Dopamine (3-hydroxytyramine) in the central nervous system and its relation to the Parkinson syndrome in man (translation from German). Deutsch. Med. Wochenschr. 87, 1807-1810 (1962).
4. S. B. Dunnett, Motor function(s) of the nigrostriatal dopamine system: Studies of lesions and behavior, in Handbook of Chemical Neuroanatomy Vol. 21, Dopamine, S. B. Dunnett, M. Bentivoglio, A. Björklund, T. Hökfelt, Eds. (Elsevier, Oxford, 2005), pp. 237-301.
5. J. W. Langston, MPTP: Insights into the etiology of Parkinson's disease. Eur. Neurol. 26 (suppl. 1), 2-10 (1987).
6. S. Jarraya, S. Boulet, G. S. Ralph, C. Jan, G. Bonvento, M. Azzouz, J. E. Miskin, M. Shin, T. Delzescaux, X. Drouot, A.-S. Hérard, D. M. Day, E. Brouillet, S. M. Kingsman, P. Hantraye, K. A. Mitrophanous, N. D. Mazarakis, S. Palfi, Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia. Sci. Transl. Med. 2, 2ra4 (2009).
7. J. L. Eberling, W. J. Jagust, C. W. Christine, P. Starr, P. Larson, K. S. Bankiewicz, M. J. Aminoff, Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 70, 1980-1983 (2008).
8. J. K. Andersen, Arvid Carlsson: An early pioneer in translational medicine. Sci. Transl. Med. 1, 2ps3 (2009).
9. G. C. Cotzias, M. H. Van Woert, L. M. Schiffer, Aromatic amino acids and modification of parkinsonism. N. Engl. J. Med. 276, 374-379 (1967).
10. M. M. Mouradian, J. L. Juncos, G. Fabbrini, T. N. Chase, Motor fluctuations in Parkinson's disease: Pathogenetic and therapeutic studies. Ann. Neurol. 22, 475-479 (1987).
11. J. A. Obeso, C. W. Olanow, J. G. Nutt, Levodopa motor complications in Parkinson's disease. Trends Neurosci. 23 (suppl.), S2-S7 (2000).
12. C. W. Olanow, J. A. Obeso, F. Stocchi, Continuous dop-amine-receptor treatment of Parkinson's disease: Scientific rationale and clinical implications. Lancet Neurol. 5, 677-687 (2006).
13. D. Nyholm, H. Askmark, C. Gomes-Trolin, T. Knutson, H. Lennernäs, C. Nyström, S.-M. Aquilonius, Optimizing levodopa pharmacokinetics: Intestinal infusion versus oral sustained-release tablets. Clin. Neuropharmacol. 26, 156-163 (2003).
14. M. M. Mouradian, I. J. Heuser, F. Baronti, T. N. Chase, Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann. Neurol. 27, 18-23 (1990).
15. T. Björklund, D. Kirik, Scientific rationale for the development of gene therapy strategies for Parkinson's disease. Biochim. Biophys. Acta 1792, 703-713 (2009).
16. M. M. Mouradian, T. N. Chase, Gene therapy for Parkinson's disease: An approach to the prevention or palliation of levodopa-associated motor complications. Exp. Neurol. 144, 51-57 (1997).
17. Oxford Biomedica announces update on phase I/II study of ProSavin in Parkinson's disease, 13 July 2009 (www.oxfordbiomedica.co.uk/page.asp?pageid= 59&newsid=236).
18. K. S. Bankiewicz, M. Daadi, P. Pivirotto, J. Bringas, L. Sanftner, J. Cunningham, J. R. Forsayeth, J. L. Eberling, Focal striatal dopamine may potentiate dyskinesias in parkinsonian monkeys. Exp. Neurol. 197, 363-372 (2006).
19. K. S. Bankiewicz, J. Forsayeth, J. L. Eberling, R. Sanchez- Pernaute, P. Pivirotto, J. Bringas, P. Herscovitch, R. E. Carson, W. Eckelman, B. Reutter, J. Cunningham, Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol. Ther. 14, 564-570 (2006).
20. J. R. Forsayeth, J. L. Eberling, L. M. Sanftner, Z. Zhen, P. Pivirotto, J. Bringas, J. Cunningham, K. S. Bankiewicz, A dose-ranging study of AAV-hAADC therapy in Parkinsonian monkeys. Mol. Ther. 14, 571-577 (2006).
21. T. Nagatsu, T. Yamamoto, T. Kato, A new and highly sensitive voltammetric assay for aromatic l-amino acid decarboxylase activity by high-performance liquid chromatography. Anal. Biochem. 100, 160-165 (1979).
22. K. Lloyd, O. Hornykiewicz, Parkinson's disease: Activity of l-dopa decarboxylase in discrete brain regions. Science 170, 1212-1213 (1970).
23. M. Azzouz, E. Martin-Rendon, R. D. Barber, K. A. Mitrophanous, E. E. Carter, J. B. Rohll, S. M. Kingsman, A. J. Kingsman, N. D. Mazarakis, Multicistronic lentiviral vec-tor- mediated striatal gene transfer of aromatic l-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson's disease. J. Neurosci. 22, 10302- 10312 (2002).
24. C. Bencsics, S. R. Wachtel, S. Milstien, K. Hatakeyama, J. B. Becker, U. J. Kang, Double transduction with GTP cyclohydrolase I and tyrosine hydroxylase is necessary for spontaneous synthesis of l-DOPA by primary fibroblasts. J. Neurosci. 16, 4449-4456 (1996).
25. O. Corti, A. Sánchez-Capelo, P. Colin, N. Hanoun, M. Hamon, J. Mallet, Long-term doxycycline-controlled expression of human tyrosine hydroxylase after direct ade-novirus- mediated gene transfer to a rat model of Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 96, 12120-12125 (1999).
26. S. R. Wachtel, C. Bencsics, U. J. Kang, Role of aromatic lamino acid decarboxylase for dopamine replacement by genetically modified fibroblasts in a rat model of Parkinson's disease. J. Neurochem. 69, 2055-2063 (1997).
27. S. C. Kumer, K. E. Vrana, Intricate regulation of tyrosine hydroxylase activity and gene expression. J. Neurochem. 67, 443-462 (1996).
28. S.-I. Muramatsu, K.-I. Fujimoto, K. Ikeguchi, N. Shizuma, K. Kawasaki, F. Ono, Y. Shen, L. Wang, H. Mizukami, A. Kume, M. Matsumura, I. Nagatsu, F. Urano, H. Ichinose, T. Nagatsu, K. Terao, I. Nakano, K. Ozawa, Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes. Hum. Gene Ther. 13, 345-354 (2002).
29. Y. Shen, S. I. Muramatsu, K. Ikeguchi, K. I. Fujimoto, D. S. Fan, M. Ogawa, H. Mizukami, M. Urabe, A. Kume, I. Nagatsu, F. Urano, T. Suzuki, H. Ichinose, T. Nagatsu, J. Monahan, I. Nakano, K. Ozawa, Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-l-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease. Hum. Gene Ther. 11, 1509-1519 (2000).
30. L. Chen, Y. Ding, B. Cagniard, A. D. Van Laar, A. Mortimer, W. Chi, T. G. Hastings, U. J. Kang, X. Zhuang, Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice. J. Neurosci. 28, 425-433 (2008).
31. D. Kirik, B. Georgievska, C. Burger, C. Winkler, N. Muzyczka, R. J. Mandel, A. Björklund, Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of l-dopa using rAAV-mediated gene transfer. Proc. Natl. Acad. Sci. U.S.A. 99, 4708-4713 (2002).
32. T. Carlsson, C. Winkler, C. Burger, N. Muzyczka, R. J. Mandel, A. Cenci, A. Björklund, D. Kirik, Reversal of dyskinesias in an animal model of Parkinson's disease by continuous l-DOPA delivery using rAAV vectors. Brain 128, 559-569 (2005).
33. L. Leriche, T. Björklund, N. Breysse, L. Besret, M. C. Grégoire, T. Carlsson, F. Dollé, R. J. Mandel, N. Déglon, P. Hantraye, D. Kirik, Positron emission tomography imaging demonstrates correlation between behavioral recovery and correction of dopamine neurotransmission after gene therapy. J. Neurosci. 29, 1544-1553 (2009).
34. M. T. Carta, T. Carlsson, D. Kirik, A. Björklund, Dopamine released from 5-HT terminals is the cause of l-DOPAinduced dyskinesia in parkinsonian rats. Brain 130, 1819-1833 (2007).
35. D. A. Williams, Gene therapy continues to mature and to face challenges. Mol. Ther. 17, 1305-1306 (2009).